- Home
- EARN vs PLRX Comparison
EARN vs PLRX Comparison
Compare EARN & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- PLRX
- Stock Information
- Founded
- EARN 2012
- PLRX 2015
- Country
- EARN United States
- PLRX United States
- Employees
- EARN N/A
- PLRX N/A
- Industry
- EARN Real Estate Investment Trusts
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- EARN Real Estate
- PLRX Health Care
- Exchange
- EARN Nasdaq
- PLRX Nasdaq
- Market Cap
- EARN 187.6M
- PLRX 165.5M
- IPO Year
- EARN 2013
- PLRX 2020
- Fundamental
- Price
- EARN $5.42
- PLRX $1.35
- Analyst Decision
- EARN Hold
- PLRX Hold
- Analyst Count
- EARN 1
- PLRX 10
- Target Price
- EARN N/A
- PLRX $9.79
- AVG Volume (30 Days)
- EARN 789.5K
- PLRX 2.5M
- Earning Date
- EARN 03-12-2025
- PLRX 03-03-2025
- Dividend Yield
- EARN 17.75%
- PLRX N/A
- EPS Growth
- EARN N/A
- PLRX N/A
- EPS
- EARN 0.28
- PLRX N/A
- Revenue
- EARN $15,069,000.00
- PLRX N/A
- Revenue This Year
- EARN $109.38
- PLRX N/A
- Revenue Next Year
- EARN $38.79
- PLRX $46.66
- P/E Ratio
- EARN $19.37
- PLRX N/A
- Revenue Growth
- EARN N/A
- PLRX N/A
- 52 Week Low
- EARN $5.41
- PLRX $1.26
- 52 Week High
- EARN $7.26
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- EARN 23.79
- PLRX 25.56
- Support Level
- EARN $5.77
- PLRX $1.42
- Resistance Level
- EARN $5.98
- PLRX $1.56
- Average True Range (ATR)
- EARN 0.15
- PLRX 0.12
- MACD
- EARN -0.01
- PLRX 0.24
- Stochastic Oscillator
- EARN 0.54
- PLRX 4.49
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.